HONOLULU — Children with uncontrolled moderate to severe asthma experienced fewer severe exacerbations requiring systemic corticosteroids when treated with dupilumab, according to a poster presented at the CHEST Annual Meeting.
These children experienced reductions in their corticosteroid burden regardless of their prior exacerbation history, Rebecca Gall, MD, medical director, immunology, Regeneron Pharmaceuticals, and colleagues wrote.
“Despite standard-of-care therapy such as inhaled corticosteroids, children with uncontrolled moderate to severe asthma are at risk of severe